Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00672321|
Recruitment Status : Unknown
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : May 6, 2008
Last Update Posted : August 12, 2013
RATIONALE: Gathering information about vitamin D supplementation and sun exposure in patients with melanoma may help doctors learn more about the disease and find what may affect cancer relapse.
PURPOSE: This clinical trial is studying vitamin D supplementation and sun exposure in patients who have undergone surgery for stage IB, stage II, or stage IIIA melanoma.
|Condition or disease||Intervention/treatment|
|Melanoma (Skin)||Genetic: gene expression analysis Genetic: mutation analysis Genetic: polymorphism analysis Other: laboratory biomarker analysis Other: questionnaire administration|
- To examine the findings of the pilot study, that vitamin D supplementation in combination with vitamin D receptor (VDR) polymorphisms protects from late relapse (after 3 years) in patients who have had melanoma.
- To investigate the effects of vitamin D supplement dosage in reducing the risk of late relapse.
- To examine if vitamin D supplementation in combination with particular VDR polymorphisms protects from early relapse (before 3 years).
- To examine if serum levels of vitamin D correlate with risk of relapse in groups of patients with different VDR polymorphisms.
- To examine the effect of vitamin supplementation and VDR status on time to relapse and survival in these patients.
- To examine other factors that may affect risk of relapse by assembling a tissue (genomic DNA and serum) resource.
- To investigate the effect of exposure to incidental drugs, such as statins, on risk of relapse in these patients.
OUTLINE: Patients are stratified according to disease relapse in the past 5 years (yes vs no).
Patients are asked to complete a food frequency questionnaire focusing on vitamin D and the following area: supplementation of diet with vitamins/fish oil and duration of use; sun exposure and sunscreen-use per decade prior to and after diagnosis. Patients are also asked to provide a blood sample for serum and DNA analysis. Consenting patients are also tagged with the Office of National Statistics to allow passive follow up.
Stored tissue from the patient's primary melanoma may be used to corroborate research findings using immunohistochemistry or studies of gene expression, polymorphism, or mutation.
|Study Type :||Observational|
|Estimated Enrollment :||2774 participants|
|Official Title:||Melanoma Lifestyle Study|
|Study Start Date :||December 2007|
|Estimated Primary Completion Date :||September 2010|
- Odds ratio (OR) for vitamin D supplementation in relapse
- OR for vitamin D supplementation in patients with specific VDR genotypes
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00672321
|Leeds Cancer Centre at St. James's University Hospital||Recruiting|
|Leeds, England, United Kingdom, LS9 7TF|
|Contact: Contact Person 44-113-206-6534 firstname.lastname@example.org|
|Principal Investigator:||Julia Newton Bishop, MD||Leeds Cancer Centre at St. James's University Hospital|